Business Description
Entrada Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US29384C1080
Description
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.33 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.15 | |||||
| Debt-to-EBITDA | 1 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 4.66 | |||||
| Beneish M-Score | -1.25 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 80.2 | |||||
| 3-Year EPS without NRI Growth Rate | 46.3 | |||||
| Future 3-5Y Total Revenue Growth Rate | -31.26 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 78.84 | |||||
| 9-Day RSI | 69.1 | |||||
| 14-Day RSI | 65.42 | |||||
| 6-1 Month Momentum % | 12.29 | |||||
| 12-1 Month Momentum % | 35.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.59 | |||||
| Quick Ratio | 6.59 | |||||
| Cash Ratio | 6.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17.8 | |||||
| Shareholder Yield % | -2.63 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | 26.85 | |||||
| Net Margin % | 25.53 | |||||
| FCF Margin % | -8.11 | |||||
| ROE % | 17.06 | |||||
| ROA % | 10.56 | |||||
| ROIC % | 19.16 | |||||
| ROC (Joel Greenblatt) % | 64.2 | |||||
| ROCE % | 14.84 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 12.47 | |||||
| Forward PE Ratio | 43.92 | |||||
| PE Ratio without NRI | 12.47 | |||||
| PS Ratio | 3.17 | |||||
| PB Ratio | 1.75 | |||||
| Price-to-Tangible-Book | 1.75 | |||||
| EV-to-EBIT | 5.83 | |||||
| EV-to-EBITDA | 5.49 | |||||
| EV-to-Revenue | 1.56 | |||||
| EV-to-Forward-Revenue | 8.53 | |||||
| EV-to-FCF | -19.29 | |||||
| Price-to-Graham-Number | 0.99 | |||||
| Price-to-Net-Current-Asset-Value | 2.23 | |||||
| Price-to-Net-Cash | 2.34 | |||||
| Earnings Yield (Greenblatt) % | 17.15 | |||||
| FCF Yield % | -2.35 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TRDA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Entrada Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 215.232 | ||
| EPS (TTM) ($) | 1.59 | ||
| Beta | -0.25 | ||
| Volatility % | 51.75 | ||
| 14-Day RSI | 65.42 | ||
| 14-Day ATR ($) | 0.834502 | ||
| 20-Day SMA ($) | 18.6805 | ||
| 12-1 Month Momentum % | 35.92 | ||
| 52-Week Range ($) | 11.35 - 20.49 | ||
| Shares Outstanding (Mil) | 37.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Entrada Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Entrada Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Entrada Therapeutics Inc Frequently Asked Questions
What is Entrada Therapeutics Inc(TRDA)'s stock price today?
The current price of TRDA is $19.83. The 52 week high of TRDA is $20.49 and 52 week low is $11.35.
When is next earnings date of Entrada Therapeutics Inc(TRDA)?
The next earnings date of Entrada Therapeutics Inc(TRDA) is 2025-03-13 Est..
Does Entrada Therapeutics Inc(TRDA) pay dividends? If so, how much?
Entrada Therapeutics Inc(TRDA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers